Blue Ocean Capital Strengthens Nordic Market Presence, Spearheading Cross-Border Biopharmaceutical Collaboration

On October 13, Yang Feng, founding partner and CEO of Blue Ocean Capital, was invited to attend the "Nordic Life Science Day" event held in Gothenburg, Sweden. He participated in panel discussions and multiple one-on-one meetings, engaging deeply with potential investment projects. As one of the more influential life science events in Europe, the event was hosted by a Swedish biotechnology industry organization, bringing together top global pharmaceutical companies, research institutions, investors, and entrepreneurs. The discussions focused on cutting-edge fields such as cell and gene therapy, digital health, and AI-driven drug discovery, exploring new pathways for scientific breakthroughs and industry collaboration.

During the panel discussion, Yang Feng shared Blue Ocean Capital's practices and insights in linking China with the global biopharmaceutical innovation ecosystem. He specifically mentioned that Blue Ocean Capital has invested in multiple life science innovation companies founded by faculty members of the Karolinska Institute in Sweden. Among them, Ribo Life Science has grown into a leading small nucleic acid pharmaceutical company in China and is about to enter the Hong Kong capital market. It has also established a subsidiary and international research and development center in Gothenburg, effectively advancing the development process of the global nucleic acid drug industry.

Blue Ocean Capital, as a professional investment institution in the healthcare field rooted in China and with a global presence, adheres to the concept of "global vision and empowering investment" and is committed to becomingChina PowerA key link to the world's top biopharmaceutical innovation. Currently, Blue Ocean Capital manages dual-currency funds in RMB and USD equivalent to several hundred million dollars cumulatively. Its investment spans critical stages from early R&D to growth-phase commercialization. Based on this strategy, Blue Ocean Capital has successfully identified and invested in industry-leading companies with global innovation capabilities, such as Zonlink Medical, Signet Therapeutics, Koka Medical, Boan Biotech, Ribo Life Science, and HighTide BioPharma. This series of precise investment strategies has also earned Blue Ocean Capital recognition from authoritative institutions, winning honors such as "Top 10 Emerging Investors in China's Best Private Equity Investment," "Top 10 Cases in China's Best Private Equity Investment," and "Best M&A Financing Award."

The outstanding investment capability of Blue Ocean Capital stems from the forward-looking layout and strategic vision of its founder, Yang Feng. With over 25 years of cross-border investment experience spanning mainland China, Hong Kong, and the U.S. markets, he has a deep understanding of the full-cycle growth logic of companies from inception to IPO, especially excelling in providing the crucial "first check" during the early stages of a company’s development. Since its establishment in 2015, Blue Ocean Capital has focused its investment priorities on innovative biopharmaceuticals, showing particular preference for projects with high technological barriers and possessing global innovation and breakthrough potential.

To strengthen the professionalism of investments and the industrial linkage capabilities, Yang Feng formed a "multi-skilled" team covering R&D, clinical, and commercialization. The team members include industry experts from multinational pharmaceutical companies such as Sanofi, Philips, AstraZeneca, as well as scientists from top academic institutions in China and abroad. With extensive industry experience and a background in pharmaceutical investments, the team ensures that Blue Ocean Capital achieves professional depth in project screening, risk management, and post-investment support. In addition to providing financial backing to enterprises, the team also offers full-chain support to invested companies, ranging from R&D and clinical strategies to international development.

Under the leadership of Yang Feng, the team has led several landmark transactions with industry influence. The most representative case is the privatization transaction of China Cord Blood Corporation (CO Group), a U.S.-listed company. In this complex cross-border capital operation, Yang Feng led the design of a transaction structure that spanned the U.S., Hong Kong, and A-share markets. The acquisition and exit were efficiently completed in less than two years, not only generating hundreds of millions of dollars in returns for investors but also setting a benchmark in the industry with its "fast, accurate, and stable" execution efficiency. This also laid a solid foundation for Blue Ocean Capital’s subsequent systematic expansion into global markets such as Europe and North America.

Blue Ocean Capital's in-depth layout in the Nordic market represents a further development and implementation of its international investment strategy, with multiple projects currently in the late execution stage. While continuing to invest, Blue Ocean Capital will also actively assist and promote the establishment of joint ventures in China by its portfolio companies, facilitating their entry into the Chinese market. Looking ahead, Yang Feng stated that he will continue to lead Blue Ocean Capital in leveraging its cross-border resource integration capabilities and deep industry empowerment system to play a significant role in the global biopharmaceutical innovation landscape, acting as a bridge and driver linking Eastern and Western innovation.